Navigation Links
Schering-Plough CEO Buys $2 Million in Common Shares
Date:4/24/2008

KENILWORTH, N.J., April 24 /PRNewswire-FirstCall/ -- Schering-Plough Corporation announced today that Chairman and CEO Fred Hassan purchased just over $2 million of Schering-Plough common stock, or 110, 000 shares at an average purchase price of $18.26 per share.

"As I said when I announced my intention to purchase these shares in January, this investment in Schering-Plough reflects my long-term confidence in the company, its products -- including ZETIA and VYTORIN -- and our late- stage pipeline," said Hassan.

Hassan has said on January 18 that he intended to purchase the shares as soon as the transaction received legal clearance. That clearance was issued this morning, based upon first quarter earnings having been reported yesterday.

Full details of the purchase will be reported on a Form 4 filed with the SEC and available on Schering-Plough's Web site today or tomorrow.

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is http://www.schering-plough.com.


'/>"/>
SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Schering-Plough Announces Planned Divestiture of Select Animal Health Products in Europe
2. Schering-Plough Reports Financial Results for First Quarter of 2008
3. Schering-Plough Schedules Conference Call and Webcast for 2008 First Quarter Earnings
4. Schering-Plough Launches Productivity Transformation Program To Confront New Challenges
5. Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
6. Schering-Plough Announces Filing of U.S. Application for OTC ZEGERID(R)
7. Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year
8. Schering-Plough and OraSure Technologies Sign International Collaboration for Rapid Point-of-Care Oral Hepatitis C Test
9. Schering-Plough Announces Organizational Changes at Schering-Plough Research Institute
10. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
11. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... For today, Stock-Callers.com redirects investors, attention to Biotechnology, ... research aimed at treating diseases and medical conditions. Under evaluation ... (NASDAQ: KERX), Kite Pharma Inc. (NASDAQ: KITE), and ZIOPHARM Oncology ... complimentary research reports on these stocks now at: ... http://stock-callers.com/registration Biostage ...
(Date:4/19/2017)... ... April 19, 2017 , ... Nobilis Therapeutics ... Company Seeks to Leverage Clinical Data in its Upcoming Post Traumatic Stress Disorder Trial ... an 81 patient clinical trial assessing efficacy of its NBTX-001, a xenon-based therapeutic in ...
(Date:4/19/2017)... Calif. , April 19, 2017  As ... Drug Abuse and Heroin Summit ,  Proove® Biosciences, ... study analyzing genetics, environmental, and lifestyle factors to ... from the University of Southern California (USC), the ... , and Proove publish results showing that Proove ...
(Date:4/18/2017)... ... April 18, 2017 , ... ... Channel Partners 2017 Next-Gen Solution Provider. , Channel Partners program recognizes IT and ... their vision, innovation, and advocacy of the channel during transition and convergence. CallTower ...
Breaking Biology Technology:
(Date:3/27/2017)... 27, 2017  Catholic Health Services (CHS) has ... Society (HIMSS) Analytics for achieving Stage 6 on ... . In addition, CHS previously earned a place ... an electronic medical record (EMR). "HIMSS ... of EMR usage in an outpatient setting.  This ...
(Date:3/23/2017)... , March 23, 2017 The report "Gesture Recognition ... Biometric), Industry, and Geography - Global Forecast to 2022", published by MarketsandMarkets, the ... a CAGR of 29.63% between 2017 and 2022. ... ... ...
(Date:3/22/2017)... YORK , March 21, 2017 ... Marketing Cloud used by retailers such as 1-800-Flowers ... its platform — Product Recommendations and Replenishment. Using Optimove,s ... give more personalized product and replenishment recommendations to ... but also on predictions of customer intent drawn ...
Breaking Biology News(10 mins):